--- title: "Polaryx Therapeutics | 10-K: FY2025 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/283985661.md" datetime: "2026-04-24T10:56:10.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283985661.md) - [en](https://longbridge.com/en/news/283985661.md) - [zh-HK](https://longbridge.com/zh-HK/news/283985661.md) --- # Polaryx Therapeutics | 10-K: FY2025 Revenue: USD 0 Revenue: As of FY2025, the actual value is USD 0. EPS: As of FY2025, the actual value is USD -0.2. EBIT: As of FY2025, the actual value is USD -7.821 M. Polaryx Therapeutics, Inc. operates with a singular business focus on rare, pediatric lysosomal storage disorders, and all reported financial metrics reflect this focus . #### Net Loss and Accumulated Deficit Net loss was - $8,985 thousand for the year ended December 31, 2025, showing an improvement compared to - $30,356 thousand for the year ended December 31, 2024 . As of December 31, 2025, the accumulated deficit was approximately - $99.6 million . #### Operating Expenses Research and Development (R&D) expenses increased to $6,266 thousand for the year ended December 31, 2025, from $2,811 thousand for the year ended December 31, 2024, representing a $3,455 thousand increase primarily due to consulting expenses, Rush Master Services Agreement (MSA) expenses, CRO services, and stock-based compensation . General and Administrative (G&A) expenses slightly increased to $1,555 thousand for the year ended December 31, 2025, from $1,541 thousand for the year ended December 31, 2024, a $14 thousand increase mainly due to increased audit and consulting expenses, partially offset by decreased stock-based compensation . Total operating expenses increased to $7,821 thousand for the year ended December 31, 2025, from $4,352 thousand for the year ended December 31, 2024 . The operating loss was - $7,821 thousand for the year ended December 31, 2025, compared to - $4,352 thousand for the year ended December 31, 2024 . #### Other Expenses Direct Listing Offering Costs of $1,164 thousand were incurred for the year ended December 31, 2025, with no comparable costs in 2024 . No expense was recorded for the recapitalization of common stock in 2025, compared to - $26,004 thousand in 2024 . #### Cash Flow Net cash used in operating activities increased to - $3,944 thousand for the year ended December 31, 2025, from - $2,573 thousand for the year ended December 31, 2024 . Net cash provided by financing activities decreased to $4,466 thousand for the year ended December 31, 2025, from $7,192 thousand for the year ended December 31, 2024 . The ending balance of cash and cash equivalents was $5,143 thousand as of December 31, 2025, an increase from $4,621 thousand as of December 31, 2024 . #### Working Capital As of December 31, 2025, working capital was $4.6 million . #### Unique Operational Metrics Polaryx Therapeutics, Inc.’s pipeline includes PLX-200 (clinical-stage oral small molecule), PLX-300 (novel oral small molecule in IND-enabling studies), PLX-100 (preclinical orally administrable combination therapy), and PLX-400 (preclinical novel gene therapy) . Since its inception, the company has raised $21.7 million, primarily through equity securities sales . PLX-200 has received three Orphan Drug Designations (ODD) and Fast Track designation for CLN2 and CLN3, while PLX-300 has received three ODDs and Rare Pediatric Drug designation (RPD), and PLX-100 has received one ODD . #### Outlook / Guidance Polaryx Therapeutics, Inc. expects R&D and G&A expenses to increase significantly as it advances its lead product candidates through clinical development and expands its administrative headcount as a public company . The company anticipates initiating the SOTERIA (PLX-200-600) Phase 2 basket trial in the second half of 2026, with initial enrollment for CLN2 and CLN3 cohorts expected to begin at that time . Current cash and cash equivalents are projected to fund operations through the third quarter of 2026, after which substantial additional funding will be required . ### Related Stocks - [PLYX.US](https://longbridge.com/en/quote/PLYX.US.md) ## Related News & Research - [Dear Future SpaceX (SPCX) Stock Fans, Mark Your Calendars for June 12](https://longbridge.com/en/news/286809659.md) - [Claritas Rx Strengthens Executive Team with New CRO and Two VP Promotions](https://longbridge.com/en/news/286794376.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [Bristow Spotlights Advanced Air Mobility Milestones and Safety Performance in 2025 Sustainability Report | VTOL Stock News](https://longbridge.com/en/news/286912514.md) - [Dear D-Wave Quantum Stock Fans, Mark Your Calendars for May 12](https://longbridge.com/en/news/285977949.md)